Pure Primary Small Cell Carcinoma of the Prostate

Patel, Arpan; Ball, Adam J.; Chappell, M. E.

doi:10.1111/j.1464-410x.1993.tb00739.x

Cited by 9 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone and soft tissue metastases of SCPC cannot be treated effectively with cisplatin-etoposide or cyclophosphamide, doxorubicin, and vincristine chemotherapies that mostly have toxic side effects [18, 19]. Despite chemotherapy, the mean survival time for SCPC is only 7 months [20]. Brammer et al reported a period of full remission of 36 months in a case with metastatic combined adenocarcinoma and small cell prostate carcinoma at the stage T2cN1M1c with intense systemic chemotherapy (6 courses of etoposide, cisplatin 100 mg/m 2 ), antiandrogen therapy, and radiotherapy of 75 Gy to the pelvic region and 45 Gy to regional lymph nodes [21].…”

Section: Discussionmentioning

confidence: 99%

Small Cell Prostate Carcinoma: A Case Report and Review of the Literature

Demirtaş

Sahin²,

Öztürk³

et al. 2013

Case Reports in Urology

View full text Add to dashboard Cite

Small cell prostate cancer constitutes less than 1% of all prostate cancers and has a poor prognosis. A 60-year-old male patient presented with dysuria, pollakiuria, and nocturia of about 1-year duration.The total PSA level at admission was 47.50 ng/mL. The prostate needle biopsy result was reported as adenocarcinoma Gleason 5 + 3. The patient underwent transurethral prostate resection (TUR-P) and bilateral orchiectomy. The TUR-P pathology result was consistent with small cell neuroendocrine carcinoma. He was offered systemic chemotherapy but refused it. Examinations and tests at the third postoperative month showed diffuse liver metastasis and vertebral bone metastasis. He died at the 6 months after surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Small Cell Prostate Carcinoma: A Case Report and Review of the Literature

Demirtaş

Sahin²,

Öztürk³

et al. 2013

Case Reports in Urology

View full text Add to dashboard Cite

show abstract

“…The histogenesis of SCC of the prostate remains controversial. Some scholars preferred the hypothesis that SCC was derived from malignant transformation of normal prostate neuroendocrine cells [11]. However, it has been shown that neuroendocrine cells in the normal prostate epithelium represented postmitotic cells and no longer had proliferative activity.…”

Section: Discussionmentioning

confidence: 99%

Clinical Analysis of Patients with Small Cell Prostate Carcinoma

Hao¹,

Wu²,

Hong³

et al. 2011

Am. J. Biomed. Sci.

View full text Add to dashboard Cite

The aim of this work was to investigate the prognostic value of the small cell prostate carcinoma. The data of patients with prostate carcinoma were retrospectively analyzed in this study, including the immunohistochemical methods, PSA level, Gleason score and the patients survival time. The tumor specimens were stained by neuron specific enolase(NSE), synaptophysin (SYN), chromogranin A (CgA) and NED (Neuroendocrine differentiation). Small cell carcinoma of prostate was detected in 5 cases by biopsy or autopsy. Metabasis was found in 4 patients when the small cell prostate carcinoma was diagnosed. One patient died post-diagnosis of 1 month, one patient died in 6 months, while the other 3 patients died in 3 years. The 5 year survival rate of patients with the small cell prostate carcinoma was significantly lower than that of the other prostate carcinoma patients. The expression of NED has positive correlation to Gleason score. NED was related to the prostate carcinoma patients' surviva1. The results indicated that the combination detection of NED markers and Gleason score could provide useful information of prognosis for the patients with small cell prostate carcinoma. The progression to small cell prostate carcinoma indicated a poor prognosis and slight changes in the serum prostate-specific antigen level. Early diagnosis and early treatment might improve the prognosis of the patients diagnosed as small cell prostate carcinoma.

show abstract

“…5 Because of the rarity of the condition, no standard therapeutic regime has been developed. Reported cases have generally been managed by chemotherapeutic regimens similar to those recommended for small cell lung cancer.…”

Section: Discussionmentioning

confidence: 99%

Prostate Cancer with a Normal PSA: Small Cell Carcinoma of the Prostate - A Rare Entity

Trotz¹

2003

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

Pure small cell carcinoma of the prostate is extremely rare. When it does occur, it is usually in concordance with prostatic adenocarcinoma. Early diagnosis is difficult as the carcinoma tends to spread early to visceral organs without concordant elevation of prostate-specific antigen (PSA). Because this condition is rare, no standard treatment regimen has been established, and the overall prognosis remains poor.This case report describes clinical characteristics of a 67-year-old man with pure small cell carcinoma of the prostate. The unique clinical and biological features of this histologic type of prostate cancer are discussed. Case ReportA 67-year-old man came to the emergency department complaining of a 2-week history of progressively worsening, right, upper quadrant abdominal pain associated with night sweats and a recent 15-pound weight loss. He denied any obstructive or irritative urinary symptoms, change in bowel habits, jaundice, or overseas travel.He was under the care of a urologist for benign prostatic hypertrophy and 4 years earlier had had benign findings on a prostate biopsy. His last PSA test 4 months before his current illness was normal. Other than benign prostatic hypertrophy, his medical history was notable only for mild hypertension, which was well controlled with metoprolol. He was a social drinker, nonsmoker, and had no family history of malignancies.When examined, he was a well-nourished older adult man who was anicteric, afebrile, and had no adenopathy. Important findings were confined to his abdomen, where he had mild right upper quadrant fullness and tenderness, but no guarding or rebound tenderness. A firm, nontender prostate with an enlarged left lobe was found during a digital rectal examination. His stool was positive for occult blood.Laboratory investigations included normal complete blood count, electrolyte levels, serum urea nitrogen level, creatinine level, and coagulation studies. Findings of liver function tests were normal except for an elevated alkaline phosphatase of 239 U/L (normal, 38 -126 U/L). His PSA was 1.3 ng/mL (normal, 0 -4 ng/mL); carcinoembryonic antigen, ␣-fetoprotein, and CA 19 -9 were also within normal limits.Computerized tomography (CT) of his abdomen and pelvis showed an abnormal density in the left lobe of the prostate and multiple hypoechogenic lesions in the liver consistent with extensive metastatic disease.After evaluation in the emergency department, he was subsequently admitted to the hospital for pain control and further evaluation of what appeared to be metastatic tumor. A CT scan of the chest showed right hilar adenopathy and a small peripheral nodule of the right lung. His head CT scan was negative for metastatic disease. Upper gastrointestinal endoscopy and colonoscopy findings were benign. Immunohistochemical findings from a CT-guided liver biopsy were consistent with a diagnosis of small cell (neuroendocrine) carcinoma. The malignant cells were positive for neuron-specific enolase and chromogranin. Subsequently, a transrectal sonograph-guide...

show abstract

Pure Primary Small Cell Carcinoma of the Prostate

Cited by 9 publications

References 3 publications

Small Cell Prostate Carcinoma: A Case Report and Review of the Literature

Small Cell Prostate Carcinoma: A Case Report and Review of the Literature

Clinical Analysis of Patients with Small Cell Prostate Carcinoma

Prostate Cancer with a Normal PSA: Small Cell Carcinoma of the Prostate - A Rare Entity

Contact Info

Product

Resources

About